Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
156 participants
INTERVENTIONAL
2024-11-01
2025-05-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypothesis: It is hypothesized that thyme oil inhalation will significantly improve respiratory function parameters and asthma control levels in patients with asthma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Possible Effect of Inspiratory Muscle Training on Inflammation Markers and Oxidative Stress in Childhood Asthma
NCT05296707
Effect of Halotherapy in Children With Asthma
NCT06250452
Evaluating Effects of Curcumin in Moderate to Severe Asthmatics
NCT04353310
The Impact of Air Filtration on Asthmatic Children
NCT03282864
Dietary Supplementation With Soy Isoflavones in Asthma
NCT00277446
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Type of Study This study is a pre-test post-test randomized controlled experimental design.
Population The population comprises inpatients (N = 210) in the pulmonary ward of a Training and Research Hospital located in eastern Turkey. Based on a 95% confidence interval, 5% margin of error, and 95% power analysis, a minimum of 137 patients is required. To minimize attrition, the study aims to include 150 patients (intervention group = 50, placebo group = 50, control group = 50). Data will be collected between November 2024 and February 2025.
Intervention In this study, thyme oil aromatherapy will be applied via inhalation. The product used, with NV-2016 code, contains Nature\&Nurture thyme essential oil (10 µL) macra (Barcode No: 8697742121135, Registration No: 381751) and includes components such as 1,3 y-Terpinene, 2.7% p-Cymene, 5.6% linalool, 1.2% terpinen-4-ol, 1.2% borneol, 1.2% β-Bisabolene, 3.2% tymol, and 75.7% carvacrol. The thyme oil will be applied via an inhaler stick with patients instructed to inhale eight breaths, three times daily for four days.
Data Collection Tools Data will be collected using the "Patient Introduction Form," "Asthma Control Test," and "Asthma Symptom and Respiratory Parameters Form."
* Patient Introduction Form: Created by researchers, this form includes 12 questions regarding age, weight, height, gender, marital status, education, employment, income, occupation, family asthma history, smoking, chronic illness, and asthma diagnosis duration.
* Asthma Control Test (ACT): Developed by Nathan et al and validated by Schatz et al, the ACT is suitable for assessing asthma in patients aged 12 years and older. The test includes five questions scored on a five-point Likert scale, assessing daytime and nighttime symptoms, rescue medication usage, and impact on daily activities over the past four weeks. Scores range from 5 to 25, with higher scores indicating better asthma control. ACT reliability in Turkish (Cronbach's alpha = 0.84) was established by Uysal et al.
* Asthma Symptom and Respiratory Parameters Form: This form was designed by researchers to assess symptoms (e.g., dyspnea, cough, chest wheezing) and includes FEV1 and FEV1/FVC respiratory parameters.
Data Collection Procedure Data collection will occur in a Teaching and Research Hospital's pulmonary ward from November 2024 to February 2025. Patients will be randomized into intervention, placebo, or control groups.
* Intervention Group: Patients will inhale thyme oil via inhaler sticks with instructions on proper usage, supervised by the researcher. Each patient will complete the Patient Introduction Form, Asthma Control Test, and pre-test sections of the Asthma Symptom and Respiratory Parameters Form. Measurements of FEV1 and FEV1/FVC will be recorded. On the fourth day of hospitalization, post-test data will be collected.
* Placebo Group: Patients will receive an empty inhaler stick with usage instructions, completing the same pre- and post-test procedures as the intervention group.
* Control Group: Patients will complete pre- and post-test forms without any intervention.
Data Analysis Data analysis will be conducted using SPSS. Shapiro-Wilk Test will assess normality. Significance is set at p \< 0.05. If variables are normally distributed (p \> 0.05), parametric tests will be applied. Chi-square analysis will be used for categorical data. Paired t-tests will assess within-group differences, while repeated-measures ANOVA will test differences across groups, with variance homogeneity and multivariate normality checks.
Ethics Ethical approval for the study was obtained from the Inonu University Clinical Research Ethics Committee, and institutional permission was granted by Batman Training and Research Hospital. The protocol follows the Helsinki Declaration, and all participants will be informed about data confidentiality, their right to withdraw, and that no charges or costs will be incurred.
Research Hypotheses
The following hypotheses will be tested regarding the effects of thyme oil:
* H1: Thyme oil is effective in alleviating or reducing the severity of asthma symptoms in patients with asthma.
* H2: Thyme oil improves respiratory parameters in patients with asthma.
* H3: Thyme oil enhances asthma control in patients with asthma.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention Group
The product used, with NV-2016 code, contains Nature\&Nurture thyme essential oil (10 µL) macra (Barcode No: 8697742121135, Registration No: 381751) and includes components such as 1,3 y-Terpinene, 2.7% p-Cymene, 5.6% linalool, 1.2% terpinen-4-ol, 1.2% borneol, 1.2% β-Bisabolene, 3.2% tymol, and 75.7% carvacrol. The thyme oil will be applied via an inhaler stick with patients instructed to inhale eight breaths, three times daily for four days.
Experimental
Patients will inhale thyme oil via inhaler sticks with instructions on proper usage, supervised by the researcher. Each patient will complete the Patient Introduction Form, Asthma Control Test, and pre-test sections of the Asthma Symptom and Respiratory Parameters Form. Measurements of FEV1 and FEV1/FVC will be recorded. On the fourth day of hospitalization, post-test data will be collected.
Placebo Group
Patients will receive an empty inhaler stick with usage instructions, completing the same pre- and post-test procedures as the intervention group.
Placebo
Patients will receive an empty inhaler stick with usage instructions, completing the same pre- and post-test procedures as the intervention group.
Control
Patients will complete pre- and post-test forms without any intervention.
Control (Standard treatment)
Patients will complete pre- and post-test forms without any intervention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Experimental
Patients will inhale thyme oil via inhaler sticks with instructions on proper usage, supervised by the researcher. Each patient will complete the Patient Introduction Form, Asthma Control Test, and pre-test sections of the Asthma Symptom and Respiratory Parameters Form. Measurements of FEV1 and FEV1/FVC will be recorded. On the fourth day of hospitalization, post-test data will be collected.
Placebo
Patients will receive an empty inhaler stick with usage instructions, completing the same pre- and post-test procedures as the intervention group.
Control (Standard treatment)
Patients will complete pre- and post-test forms without any intervention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients admitted on their first day in the pulmonology ward,
* Age 18 or older,
* Alert and conscious,
* Open to communication and cooperation,
* Willing to participate in the study.
Exclusion Criteria
* Patients with pregnancy,
* Patients with dementia and/or other organic mental disorders,
* Patients with any psychiatric diagnosis, and
* Patients who do not wish to participate in the study will be excluded.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Inonu University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zeliha CENGİZ
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
A patient in eastern Turkey
Batman, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Alavinezhad A, Hedayati M, Boskabady MH. The effect of Zataria multiflora and carvacrol on wheezing, FEV1 and plasma levels of nitrite in asthmatic patients. Avicenna J Phytomed. 2017 Nov-Dec;7(6):531-541.
Uysal MA, Mungan D, Yorgancioglu A, Yildiz F, Akgun M, Gemicioglu B, Turktas H; Turkish Asthma Control Test (TACT) Study Group. The validation of the Turkish version of Asthma Control Test. Qual Life Res. 2013 Sep;22(7):1773-9. doi: 10.1007/s11136-012-0309-1. Epub 2012 Nov 10.
Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004 Jan;113(1):59-65. doi: 10.1016/j.jaci.2003.09.008.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024/126
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.